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Since the description of the chemical properties
and hormonal interactions of prostaglandins (PG's)
[1], several studies have suggested a role for these
ubiquitous fatty acids in the maintenance of water
balance [2, 3]. The localization of PG synthesis in
interstitial cells of renal medulla and papilla and in
epithelial cells of renal collecting ducts has made it
particularly attractive to postulate that PG's are
involved in the intrarenal control of water excretion
[4—7]. This postulate has now received support from
a number of in vitro studies that suggest that PG's
antagonize the hydroosmotic effect o:f antidiuretic
hormone (ADH) [2, 3]. Fewer in vivo studies have
examined the biological significance of this antago-
nism in health and disease. This report will provide
an overview of the role of PG's in water metabo-
lism. Particular emphasis will be placed on in vivo
studies examining the interaction between PG's and
the renal hydroosmotic response to ADH.
Role of prostaglandins in thirst and antidiuretic
hormone release
Under usual circumstances, water homeostasis is
maintained by a balance between thirst-mediated
fluid intake and water loss. The central nervous
system plays an important role in modulating thirst,
whereas the kidney is the major organ involved in
the regulation of water loss. Maximal renal water
conservation requires release of ADH from the
posterior pituitary and an intact renal hydroosmotic
response to ADH. Intrarenal factors that modulate
the renal hydroosmotic response to ADH include
tonicity of renal medullary interstitium, collecting
tubule anatomic and biochemical integrity, and the
rate of flow and solute content of collecting tubular
fluid. Thus, both central nervous system (thirst,
ADH release) and intrarenal factors play important
roles in renal water excretion. There is increasing
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evidence that PG's influence each of these aspects
of water metabolism.
Prostaglandins are known to be present in sub-
stantial quantities in intracranial tissue [8]. More-
over, central nervous system PG's participate in
control of such physiologic processes as cerebral
blood flow where PGE and PGF2a exert a vasocon-
strictor effect [9, 10] and in thermoregulation where
hypothalamic PG's appear to function as central
transmitters in initiation of fever [11]. Accumulating
evidence also suggests that PG's participate in
release of hormones from the anterior pituitary.
For example, PGE stimulates release of growth
hormone (GH), adrenocorticotrophic hormone
(ACTH), and thyroid-stimulating hormone (TSH)
from in vitro pituitary preparations [12—14]. More-
over, PG's inhibition with indomethacin diminishes
GH and TSH release in isolated pituitary prepa-
rations [13]. In in vivo studies, PG's appear to
enhance the release of ACTH and TSH through
stimulation of hypothalamic releasing factors [15—
18].
With regard to the posterior pituitary and ADH,
in vitro pituitary preparation studies show an effect
of PG's to stimulate ADH release [9, 20]. In studies
using organ culture of guinea pig neurohypophyseal
complex, a dose-dependent effect of PGE2 to stimu-
late ADH release was present [21]. In these studies,
prostaglandin inhibition with indomethacin also
suppressed the effects of angiotensin II (All) and
hypertonicity to release ADH. Indomethacin, how-
ever, did not influence basal ADH release. Taken
together, in vitro studies suggest an important role
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for PG's in mediating ADH release. The mechanism
of this effect has not been clarified.
The effects of PG's on ADH release have also
been studied in intact animals. Following i.v. PGE1
administration to anesthetized dogs, marked antidi-
uresis was observed [221. This antidiuresis was not
seen when equivalent doses of PGE1 were adminis-
tered to acutely hypophysectomized animals with-
out endogenous ADH. Because PGE1 also induced
significant decreases in arterial pressure, these
studies do not delineate a direct role for PG's in
ADH release. In other studies, intracarotid infusion
of PGE2 increased urine osmolality in rats indepen-
dent of changes in mean arterial pressure [19], thus
suggesting a direct central role of PG's on ADH
release.
Intraventricular administration of large doses of
PGE1 and E2 interrupt a water diuresis in the
conscious goat [23, 24] and rat [251, also suggesting
possible ADH release. But, in these intraventricular
studies, very high doses of PGE1 and PGE2 were
used, and a marked pressor response was observed
following intraventricular PG administration. In
anesthetized dogs, large doses of intraventricular
PGE2 increase plasma ADH levels, but plasma
osmolality and mean arterial pressure remain con-
stant [261. In these studies, indomethacin resulted
in a significant decline in plasma ADH levels [261.
But, indomethacin also produced hemodynamic
changes (increased arterial and left atrial pressures)
that could suppress ADH through hemodynamic
mechanisms. Most recently, PG inhibition with
indomethacin diminished urinary excretion of ADH
in normal volunteers on both normal and low sodi-
um intake [27]. If changes in urinary excretion of
ADH reflect changes in ADH secretion, then this
study provides in vivo support for a role for PG in
ADH release. Taken together, in vitro and in vivo
studies suggest that PG participate in ADH release.
But, confirmatory in vivo studies using smaller
doses of PG's in more physiologic settings are
needed. Moreover, the mechanism whereby PG's
stimulate ADH release remains to be clarified.
The effect of PG's on thirst has not been exten-
sively evaluated. In conscious goats, intraventricu-
lar PGE results in some increase in basal thirst
response and potentiates the effect of hypertonic
saline on fluid intake [23, 24]. In the rat, however,
PGE antagonizes the dipsogenic response to All
[28]. In view of accumulating evidence suggesting
an important role for PG's in mediating several
central nervous system physiologic responses, the
role of PG's in thirst merits additional evaluation.
Role of prostaglandins in intrarenal regulation qf
renal water excretion
In vitro studies. The original observations by
Orloff, Handler, and Bergstrom using the toad
bladder [29] and Grantham and Orloff using isolated
perfused rabbit renal collecting duct [30] suggested
that PGE1 and PGE2 impaired the water transport
response to ADH. These observations have subse-
quently been confirmed by other investigators [31,
32]. Moreover, the effect of cyclooxygenase inhibi-
tion and other types of PG inhibition to enhance the
in vitro hydroosmotic response to ADH also sup-
ports a direct effect of PG's to modulate cellular
ADH responses [32, 331.
The mechanism whereby PG's exert their antago-
nistic effect of ADH has not been totally clarified.
Toad bladder studies demonstrate that PGE1 antag-
onizes the hydroosmotic effect of ADH but not of
cyclic 3',5'-adenosine monophosphate (cyclic
AMP) [29, 31, 34, 35]. Because ADH increases
cyclic AMP formation by stimulating adenylate
cyclase activity, PGE most likely exerts an effect
proximal to cyclic AMP formation, such as at the
receptor site [29—31, 35, 36]. Moreover, the demon-
stration that PGE diminishes the effect of ADH to
stimulate the formation of adenylate cyclase and
cyclic AMP in toad bladder, kidney slices, and
collecting tubules further supports this contention
[14, 18, 311. Initial work by Dousa and Northrup
[36] did not find such decreases in ADH stimulated
cyclic AMP by PG in tissue slices. But, recent work
from the same group has demonstrated that ibupro-
fen, a PG inhibitor, enhances the effect of vasopres-
sin to stimulate adenylate cyclase in outer medul-
lary collecting ducts [37]. In addition, because PG
inhibition also increases cyclic-AMP-stimulated
water transport, a site of action of PG to antagonize
ADH distal to cyclic AMP has also been proposed
[38, 391.
To clarify this issue, studies were performed in
our laboratory to examine whether medullary cyclic
AMP concentrations are enhanced to a greater
extent by the same vasopressin dose administered
to PG-inhibited rats (indomethacin, 10 mg/kg) as
that administered to untreated control rats [40]. The
finding that indomethacin pretreatment enhanced
the vasopressin-mediated increase in medullary cy-
clic AMP provided further support that endogenous
PG's interfere with the cellular action of vasopres-
sin to generate cyclic AMP [40]. Because large
doses of indomethacin have been shown to inhibit
cyclic nucleotide phosphodiesterase, the increase in
cyclic AMP could have resulted from this effect
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rather than from inhibition of PG synthesis. Medul-
lary phosphodiesterase concentrations, however,
were measured in these studies and were found not
to be altered by indomethacin treatment. Moreover,
other workers have been unable to find that indo-
methacin increases the renal-slice cyclic AMP re-
sponse to ADH [36]. Interpretation of the effect of
PG's on the cyclic AMP system, however, has been
rendered difficult because large doses of PG's
(>l06 M) themselves increase renal tissue adeny-
late cyclase and cyclic AMP [35, 41, 42]. Moreover,
PG inhibitors inhibit a number of enzyme systems
and thereby exert a number of important physiolog-
ic effects [43]. Finally, intact renal tissue contains a
number of ADH-sensitive cell types such as glomer-
ular, interstitial, vascular, and tubular cells. Such
cell heterogeneity makes clear-cut interpretation of
biochemical analyses of intact renal tissue difficult.
Thus, studies using more specific PG inhibitors and
homogenous cell populations are needed to better
address this issue.
In vivo studies: (1) Overview and methodologic
problems. Although in vitro studies clearly demon-
strate that PG's antagonize the hydroosmotic action
of ADH at a cellular level, multiple potential intra-
renal effects of PG's render interpretation of in vivo
studies more difficult. In this regard, increasing
evidence suggests an important role for PG's in the
maintenance of renal hemodynamics, particularly in
response to renal ischemic insults. In studies per-
formed in our laboratory, the importance of renal
PG's in control of renal hemodynamics was exam-
ined in anesthetized dogs during a 30% reduction in
arterial blood pressure by hypotensive hemorrhage
[44, 45]. In PG-intact control animals, hemorrhage
caused a modest decrease in both glomerular filtra-
tion rate (GFR, 46 to 37 ml/min, P < 0.05) and renal
blood flow (RBF, 254 to 192 ml/min, P < 0.01). In
dogs undergoing PG inhibition, the same degree of
hemorrhage resulted in striking reductions in GFR
(47 to 5 ml/min, P < 0.001) and RBF (213 to 25
mI/mm, P < 0.001). Either unilateral renal arterial
infusion of a competitive inhibitor of All or unilat-
eral renal denervation significantly attenuated the
fall in GFR and RBF seen following hemorrhage in
PG-inhibited animals. These results indicate that
the renin-angiotensin system and renal nerves are
major renal ischemic factors during hemorrhage
that are normally opposed by PG's. Loss of the
renal vasodilatory effect of PG's in the setting of
hypotensive hemorrhage thus can markedly dimin-
ish GFR and RBF. Such reductions would decrease
distal nephron delivery of tubular fluid, thereby
limiting renal water excretion. Thus, renal hemody-
namic effects of PG's and PG inhibition are impor-
tant considerations in in vivo studies. Indeed, these
hemodynamic effects may be responsible for the
effects of PG inhibition with indomethacin to dimin-
ish renal water excretion in presumably ADH-free
animals [46].
Alterations in local environmental factors that
modulate water reabsorption across collecting duct
epithelium are additional potential mechanisms
whereby PG's could exert an in vivo effect on renal
water excretion. Thus, PG-induced changes in renal
medullary-papillary blood flow could affect mainte-
nance of renal interstitial tonicity. In this regard,
either intrarenal infusion of PG's or facilitation of
renal PG synthesis with arachidonic acid increases
inner cortical and juxtamedullary RBF [47—49] with
washout of interstitial tonicity [50]. Moreover, PG
inhibition with indomethacin diminishes inner corti-
cal RBF [47, 51], papillary plasma flow [52, 53],
RBC velocity in vasa recta of renal medulla [54],
and increases renal interstitial solute concentration
[55, 56]. Other workers, however, have been unable
to find an effect of indomethacin on papillary plas-
ma flow [56, 57]. In addition, PG's do not appear to
mediate the effect of ADH to redistribute RBF
away from outer cortex to inner cortical and juxta-
medullary areas [58]. Taken together, the effect of
PG's to regulate papillary plasma flow and thereby
modulate interstitial solute content represents an-
other potential pathway whereby PG's may modu-
late the effect of ADH. This potential mechanism,
however, requires additional evaluation.
Other environmental factors that regulate water
reabsorption across collecting duct epithelium in-
clude the solute content and rate of flow of tubular
fluid reaching the collecting duct. Thus, either a
vasodilatory influence of PG's (by diminishing pri-
marily proximal tubular peritubular physical factors
that modulate tubular fluid and electrolyte reab-
sorption) or direct tubular effects of PG's could
result in solute diuresis. Indeed, intrarenal infusion
of PG's results in renal vasodilatation and solute
diuresis comparable with intrarenal infusion of oth-
er potent renal vasodilators [59—64]. The physiolog-
ic significance of these studies is, however, difficult
to determine because pharmacologic doses were
used and because intrarenal infusion of PG's does
not mimic their normal intrarenal site of physiologic
action. Nevertheless, there is in vitro [65, 66] and in
vivo [59—64] evidence to suggest that PG's are one
of several factors that act to modulate tubular
sodium reabsorption. The mechanism of this action
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remains to be clarified. In general, the magnitude of
effect of PG's on electrolyte excretion is small when
no renal hemodynamic alterations are present.
Thus, it is unlikely that PG's exert a significant
intrarenal influence on in vivo water excretion by
this mechanism except when infused into the renal
artery in vasodilatory doses.
(2) Role of prostaglandins in renal water excre-
tion in health. Clearance studies that examined the
effects of intrarenal infusions of PGE1 initially sug-
gested that PGE exerts an anti-ADH action [60—62].
Thus, the intrarenal administration of PGE1 has
been shown uniformly to cause an increase in urine
flow and free water clearance [60—62]. The mecha-
nism of the intrarenal effect of PGE1 is difficult to
determine because of the associated increases in
renal blood flow and solute excretion, either of
which may enhance water excretion. In addition,
similar increases in water excretion have been
observed during intrarenal PGE1 administration of
animals in a ADH-free state [221. These latter
results suggested that PGE1 may enhance water
excretion by increasing distal fluid delivery out of
the proximal tubule. Such a proximal tubular effect
of PGE1, however, does not exclude an additional
direct effect of PG's on the distal nephron or even
an effect in modulating the action of ADH. The
latter possibility was suggested by the finding that
PGE1 decreases maximum free water reabsorption
more profoundly than does acetyicholine despite
comparable solute excretion rates in saline-expand-
ed dogs [60]. Although PG's could interfere with
water reabsorption by causing a washout of medul-
lary tonicity [50], the excretion of a hypotonic urine
may suggest a direct effect on the water permeabili-
ty of the collecting duct [601.
To more directly assess the role of endogenous
PG's in the in vivo control of water excretion, we
examined the effect of meclofenamate and indo-
methacin on water excretion in anesthetized dogs
rendered ADH free by acute hypophysectomy.
These dogs were undergoing a water diuresis [67].
In these studies, pretreatment with either indometh-
acm or meclofenamate potentiated the peripheral
action of exogenous vasopressin (Fig. 1). Because
this potentiation occurred despite constancy of sys-
temic hemodynamics, GFR, RBF, and osmolar
excretion, these results are compatible with an in
vivo effect of renal PG's glandins to inhibit the
action of vasopres sin to alter the water permeability
of the collecting duct. But, as previously discussed,
these inhibitors of PG synthesis may decrease med-
ullary blood flow. Such a decrease in medullary
blood flow could diminish any "washout" of inter-
stitial hypertonicity and thereby enhance the os-
motic gradient for water movement without directly
altering the cellular action of vasopressin. Measure-
ments of interstitial tonicity in this study were not
performed. Because these inhibitors of PG have
been shown not to alter baseline renal hemodynam-
ics in the conscious state, subsequent studies have
been performed in conscious man, dog, and rat by
several investigators [68—71]. Cyclooxygenase inhi-
bition with resultant diminution of renal PGE bio-
synthesis with aspirin, indomethacin, and meclo-
fenamate administration consistently enhanced the
Precontrol Vasopressin Postcontrol
Fig. 1. Effect of two consecutive boluses of 100 mU
of vasopressin on urinary osmolality in animals
with intact prostaglandins (solid lines) and animals
administered one of two inhibitors ofprostaglandin
synthesis before the second dose of vasopressin
(broken lines).
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0
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response of urinary osmolality to exogenous vaso-
pressin [68—71]. As previously reported in the dog,
these inhibitors of PG did not alter renal hemody-
namics in the conscious state. These findings pro-
vide strong support that PG's inhibit the effect of
vasopressin to generate cyclic AMP in vivo.
More recent clearance studies performed in our
laboratory have further clarified the mechanism
whereby PG's antagonize the hydroosmotic effect
of ADH [72]. In PG-intact anesthetized dogs, the
possibility was studied that PG's inhibit the action
of ADH by impairing cellular calcium uptake. If so,
verapamil, an agent that inhibits slow channel calci-
um uptake, would be expected to abolish the effect
of PG inhibition to enhance the action of ADH. In
eight PG-inhibited dogs, ADH increased the control
kidney's urinary osmolality to 650 130 mOsm/kg
H20, but in the contralateral kidney infused with
verapamil, the Usm increased only to 280 22
mOsm/kg H20. Thus, verapamil abolished the ef-
fect of PG inhibition to enhance the action of ADH.
In five additional dogs, a chemically dissimilar
inhibitor of calcium transport, proadifen, also abol-
ished the effect of PG inhibitors to enhance the
hydroosmotic effect of ADH. In these studies,
ADH increased the U0sm to 590 78 mOsm/kg
H20 in the control kidney but only to 278 11
mOsm/kg H20 in the proadifen-infused kidney.
Neither prior vasodilatation nor an increased solute
excretion with mannitol of a degree observed with
verapamil mimicked the effect of the calcium-up-
take blockers to inhibit the action of ADH. These in
vivo studies suggest that the effect of PG inhibitors
to enhance the hydroosmotic effect of vasopressin
involves cellular calcium transport.
In summary, in vivo studies clearly demonstrate
that PG's alter the hydroosmotic response to vaso-
pressin. Considerable experimental evidence sup-
ports the view that the effect involves an alteration
in the water permeability of the collecting duct.
But, because both vasopressin and PG's affect
tubular solute transport and because both may be
involved in control of intrarenal blood flow distribu-
tion, it is possible that their interaction also occurs
by one or both of these mechanisms. Recent studies
suggest that PG's impair the in vivo action of ADH
by impairing calcium membrane transport. Direct
measurements of intracellular calcium content will
be required to verify this possibility.
Role ofprostaglandins in renal water excretion in
disease: Renal water loss and nephrogenic diabetes
insipidus (Table 1). it is widely recognized that
hypokalemia can produce polyuria and a renal
Table 1. Nephrogenic diabetes insipidus states in which
prostaglandins have been postulated to play a pathogenic role
I. Hypokalemic nephropathy
2. Exposure of the renal papilla
3. Following contralateral renal artery clamping
4. Acute bacterial pyelonephritis
5. Lithium polyuria
6. Hypercalcemic nephropathy
7. Following acute renal failure
8. During "escape" from antidiuretic hormone
concentrating defect in both man and experimental
animals [73—76]. Studies performed in our labora-
tory have indicated a role for hypokalemia-induced
polydipsia in this polyuria [73]. But, polydipsia did
not account for the renal concentrating defect.
Other studies have suggested that the concentrating
defect is due to an impairment in renal interstitial
tonicity [77]. But, the observation that the ratio of
urinary to medullary tissue solutes is lower in
potassium-depleted animals than it is in normokale-
mic animals [78], as well as the observed impair-
ment of the hydroosmotic response to vasopressin
in in vitro systems exposed to low potassium con-
centrations [79], suggests a defect in the cellular
action of vasopressin as well. This cellular defect
may be related either to collecting duct structural
abnormalities [80] or to collecting duct biochemical
defects induced by the hypokalemic state [81].
Recent studies have also shown that potassium
may play a role in the control of PG biosynthesis
[82—84]. This cation inhibits biosynthesis of PGE2 in
rabbit renomedullary interstitial cells [82, 84] and in
rabbit and human renal papillary slices [83]. For
example, increasing the potassium concentrations
from 0 to 2 mEq/liter in the medium bathing the
cultured renal medullary interstitial cells diminished
the PG production per I -mEq/liter increase in the
medium's potassium concentration [82, 84]. The
mechanism whereby increasing the potassium con-
centration inhibits PG biosynthesis in this tissue
culture system has recently been elucidated [84].
Drugs that inhibit new protein synthesis do not alter
this effect. But, increasing concentrations of potas-
sium diminish the effect of exogenous arachidonic
acid added to cultured cells to increase PG biosyn-
thesis. Taken together, these results suggest that
potassium decreases PG synthesis by lowering the
availability of endogenous cellular phospholipids,
which normally serve as substrate for phospholi-
pase. Phospholipase acts on cellular lipids to form
arachidonic acid, the initial and primary regulatory
step in PG biosynthesis. In contrast, hormone-
stimulated PGE2 biosynthesis (All, bradykinin,
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ADH) is suppressed by inhibitors of protein synthe-
sis, whereas these inhibitors do not alter the effect
of exogenous arachidonic acid to stimulate PGE2
production. Thus, these hormonal agents appear to
increase PG biosynthesis by stimulating new syn-
thesis of the protein-requiring enzyme phos-
pholipase.
Because PG's exert in vitro and in vivo effects to
antagonize the hydroosmotic effect of ADH, the
possibility that an increase in medullary-papillary
PG content could be in part responsible for the renal
concentrating defect of hypokalemia appears attrac-
tive. In this regard, potassium depletion in the
human and the dog has been reported to cause large
increases in urinary PG excretion 1185—961. These
observations should be interpreted with caution
because recent studies suggest that urinary PG
excretion may be directly related to urinary flow
rate [97—99]. PG inhibition, however, may improve
the renal concentrating defect of hypokalemic dogs,
suggesting a pathogenic role [85, 87, 8811. In these
studies, however, the role of altered fluid intake on
urinary flow was not assessed. More recently, other
investigations have failed to support a pathogenic
role for PG's in hypokalemic nephropathy. Thus,
hypokalemia does not increase urinary excretion of
PG's in potassium-depleted rats or man [99—1011.
Moreover, the administration of large doses of PG
inhibitors did not improve the maximum urinary
concentrating ability in either rat [1001 or man [1021.
Taken together, these latter observations argue
against a pathogenic role for PG's in hypokalemia-
induced renal concentration defects. Clearly, more
work is needed in this area. Considering the multi-
plicity of potential mechanisms involved in the
concentrating disorder induced by hypokalemia, it
is not surprising that a PG excess cannot be clearly
identified as the only pathogenic factor.
A role for PG's in the diminution in urinary
osmolality after the renal papilla is exposed has also
been postulated [52]. The renal papilla is often
exposed during the course of animal preparation for
papillary micropuncture. In these studies, urinary
osmolality diminished by 50% 15 mm after exposure
of the renal papilla in hydropenic, anesthetized rats.
This fall in urinary osmolality was associated with a
significant increase in papillary plasma flow. Treat-
ment with either indomethacin or meclofenamate (5
mg/kg) abolished the effect of exposure of the renal
papilla to both lower urine osmolality and increase
papillary plasma flow. From these results, the au-
thors speculate that exposure of the renal papilla
results in enhanced PG synthesis. The increased PG
synthesis then increases papillary plasma flow with
siib sequent washout of medullary papillary intersti-
tial solute and lowered urinary osmolality. Neither
PG measurements nor concurrent medullary-papil-
lary solute concentrations were reported in these
studies. Moreover, lowering the urinary osmolality
itself increases the papillary plasma flow, rendering
interpretation of the effect of papillary plasma flow
on the concentrating mechanism difficult. Finally,
recent preliminary studies fail to confirm these
observations [103]. Taken together, a role for PG's
in mediating the decreased urine osmolality that
follows exposure of the renal -papilla remains to be
established;
Renal synthesis of PG's is known to be enhanced
by decreasing RBF [45, 46]. The exact mechanism
responsible for the enhancement of PG biosynthesis
in the face of renal ischemia remains uncertain. But,
All, catecholamines, and renal nerve stimulation
cause renal vasoconstriction, as well as increase
renal PG biosynthesis [45, 56]. To determine if All-
mediated increased renal PG synthesis exerts a
physiologic effect on renal water excretion, Galvez
et al induced acute increases in All by renal artery
clamping [104]. A contralateral increase in urine
volume and free water clearance was observed
independent of changes in GFR, RBF, or osmolar
excretion. The diuresis was not due to a nonspecific
hypertensive effect because trimethaphan normal-
ized blood pressure, and a diuresis continued to
occur. The effect of a competitive inhibitor of All
(saralasin) to inhibit this diuresis suggested a patho-
genic role for All in this phenomena. Angiotensin II
did not cause a diuresis by inhibiting ADH release
because a diuresis was observed in hypophysecto-
mized animals undergoing a continuous infusion of
ADH. The increase in urine volume was associated
with increases in renal venous PGE concentration
and could be prevented by indomethacin. Thus,
these results suggest that the increase in All genera-
tion induced by renal artery stenosis results in
release of PGE by the contralateral kidney. The
PGE release then antagonizes the hydroosmotic
effect of ADH, resulting in increased free water
excretion.
A defect in the urinary concentration is the
earliest functional abnormality observed in both
human and experimental pyelonephritis [57, 105].
This defect occurs soon after the initiation of the
experimental infection and disappears rapidly as the
infection clears. Although the mechanism responsi-
ble for this concentration defect is unknown, the
rapid reversibility of the defect and the occurrence
of the defect independent of histologic alterations
suggest the possibility of a role for a humoral
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substance. In this regard, Levison and Levison [57,
105] have demonstrated that the i.v. injection of
enterococci induces pyelonephritis in the rat. This
pyelonephritis is associated with a marked impair-
ment in urinary osmolality after 18 hours of dehy-
dration (experimental of 1,475 vs. control of 2,900
mOsm/kg water, P < 0.001). To evaluate a potential
role for PG's in this defect, Levison et al adminis-
tered either indomethacin or meclofenamate (10
mg/kg) [57, 105]. These cyclooxygenase inhibitors
increased urinary osmolality from 1,475 to 2,300
mOsm/kg. This improvement in urinary osmolality
could be dissociated from differences n serum
creatinine, renal histologic changes, and renal tis-
sue titers of enterococci. No measurements of
GFR, medullary tonicity, or renal PG biosynthesis
were obtained in these studies. In additional stud-
ies, a diminished papillary plasma flow was found in
these pyelonephritic rats [57]. Cyclooxygenase inhi-
bition with indomethacin again improved urinary
osmolality in these animals but did not influence the
diminished papillary plasma flow. Taken together,
these observations demonstrate that cyclooxygen-
ase inhibition improves urinary concentration fol-
lowing acute bacterial pyelonephritis. The mecha-
nisms of this concentration defect and the im-
provement noted after cyclooxygenase inhibition
require clarification but occur independent of alter-
ations in papillary plasma flow.
Additional recent reports have suggested a patho-
genic role for PG's in several nephrogenic diabetes
insipidus states. In this regard, polyuria and neph-
rogenic diabetes insipidus may be observed in 20 to
30% of patients following lithium therapy for manic
depressive psychoses [106—I 081. Preliminary re-
ports suggest that lithium increases renal PGE2
biosynthesis in dogs and man [109, 110]. More-
over, cyclooxygenase inhibition (indomethacin, 150
mg/day) in patients with lithium-induced polyuria
diminished urinary PGE excretion and urinary vol-
ume whereas the urinary osmolality increased
[110]. The improved renal concentration following
indomethacin was not associated with changes in
either GFR or solute excretion rate. These interest-
ing preliminary observations suggest that PG an-
tagonism of the hydroosmotic effect of ADH con-
tributes to lithium-induced nephrogenic diabetes
insipidus.
As discussed previously, the effect of PG's to
antagonize the hydroosmotic action of ADH ap-
pears to be a calcium-dependent phenomenon [72].
There is also evidence that one of the intracellular
effects of hypercalcemia is to stimulate PGE2 syn-
thesis. Thus, calcium ionophores augment [111] and
cellular calcium uptake inhibitors suppress [112] PG
biosynthesis in vitro. On the basis of these observa-
tions, it is tempting to speculate that a calcium-PG
interaction represents a cellular mechanism where-
by hypercalcemia induces nephrogenic diabetes in-
sipidus. In this regard, a preliminary communica-
tion demonstrates that hypercalcemia induced in
conscious rats by 1,25 dihydroxyvitamin D3 pro-
duces polyuria and increases renal PG excretion
[113]. Indomethacin suppressed urine flow and PG
excretion to basal levels. Additional studies in this
area are needed.
The role of PG's in the nephrogenic diabetes
insipidus state following nonoliguric acute renal
failure has been examined. Preliminary observa-
tions suggest a beneficial effect of indomethacin on
the polyuria observed after cis-platinum administra-
tion to rats [114]. In studies performed in our
laboratory, 50 mm of unilateral renal artery occlu-
sion in rats with a contralateral nephrectomy leads
to nonoliguric acute renal failure [115]. A marked
renal concentration defect was noted in experimen-
tal animals 7 days after induction of acute renal
failure at a time when GFR had returned to normal.
The 24-hour daily urinary PGE excretion was di-
minished in experimental animals. In addition, in-
domethacin (10 mg/kg) failed to enhance renal con-
centration. These latter studies do not, support a
role for PG's in the nephrogenic diabetes insipidus
following ischemia acute nonoliguric renal failure.
Although it is widely recognized that continued
administration of ADH leads to "escape" from the
hydroosmotic effects of this agent, the mechanism
of this "escape" has not been elucidated [1161. It is
of interest that ADH stimulates PG release from
cultured renomedullary interstitial cells, inner renal
medullary slices, and in toad urinary bladder [6, 82,
117, 118] in most but not all [119] studies. A
stimulatory effect of ADH on urinary PG excretion
has also been demonstrated in the conscious rat
[120, 121]. Because of these observations, we eval-
uated the role of PG's in a conscious rat model of
ADH escape [116]. Early escape from ADH was
associated with an increase in urinary PGE2 excre-
tion. Prevention of this increase in PGE2 excretion
with indomethacin retarded the onset of escape.
But, escape from the hydroosmotic effect of ADH
ultimately occurred, albeit at a lower plasma sodi-
um level. These preliminary observations suggest
that PGE2 may play a role in mediating early escape
from ADH.
The concentrating disorders of familial and idio-
pathic nephrogenic diabetes insipidus has also been
reported to be associated with elevated urinary PG
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excretion [122, 1231. In some of these cases, a slight
improvement in polyuria following cyclooxygenase
inhibition has been observed. The mechanisms of
this improvement need to be clarified, and these
interesting observations require confirmation.
Taken together, a number of preliminary obser-
vations suggest that the effect of PG's to antagonize
the hydroosmotic action of ADH may have signifi-
cant clinical implications in a variety of disease
states. Additional in vivo studies are necessary
before the exact pathogenic role of PG becomes
established in these disorders.
Renal water retention: Potential hyponatremia.
Despite the well-documented effect of PG inhibition
with nonsteroidal antiinflammatory agents to en-
hance the effect of ADH, clinically significant hy-
ponatremia resulting from the ubiquitous use of
drugs that inhibit PG biosynthesis has only rarely
been reported [124]. But, other agents that possibly
increase the hydroosmotic effects of ADH by inhi-
bition of PG synthesis, such as chlorpropamide
[1251, have been well-documented to cause hypona-
tremia [126]. One possible explanation for the rarity
of clinical hyponatremia after PG inhibition with
nonsteroidal antiinflammatory agents is that, as
discussed previously, PG inhibition may also direct-
ly suppress pituitary ADH release.
In addition to modulating the hydroosmotic effect
of ADH at the collecting duct, PG's also play an
important role in maintaining renal hemodynamics,
especially during stress. Thus, PG inhibition in
patients with disorders characterized by diminished
basal levels of RBF such as advanced hepatic
cirrhosis [127, 128], severe congestive heart failure
[1241, nephrotic syndrome [1291, sodium depletion
[130—132], and lupus glomerulonephritis [133] will
further diminish RBF and GFR. This subsequent
reduction in GFR can impair renal water excretion
by diminishing distal delivery of tubular fluid to the
diluting segments of the nephron. Indeed, in one
patient with severe cardiac failure [124], hyponatre-
mia developed following acute renal failure induced
by PG inhibition. Taken together, the potential for
PG inhibition to diminish renal function in patients
with diminished renal perfusion is substantial.
Thus, these agents should be used cautiously in this
setting.
Summary and conclusions
A role for PG's in the maintenance of water
balance has been established. Increasing evidence
suggests that PG's modulate the release of ADH.
With regard to renal water excretion, a role for PG's
to antagonize the hydroosmotic effect of ADH has
been well established in vitro and in vivo. The
cellular mechanism of this effect has not been
completely clarified. Substantial evidence suggest,
however, that PG's impair the effect of ADH to
stimulate renal tissue cyclic AMP. In addition, PG's
exert renal hemodynamic and tubular effects that
may be important in renal water excretion. Prelimi-
nary studies suggest a pathogenic role for PG's
in some nephrogenic diabetes-insipidus-like states.
Prostaglandin inhibition can also result in dimin-
ished renal water excretion and clinically significant
hyponatremia when administered to patients with
diminished basal renal perfusion.
Reprint requests to Dr. R. J. Anderson, Division of Renal
Diseases, Department of Medicine, university of Colorado
Health Sciences Center, 4200 East Ninth Avenue, Box C280,
Denver, Colorado 80262, USA
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